However, Tregs, which preferentially localized close to CD8+ CTLs in CML BM, protected LSCs from MHC class I–dependent CD8+ CTL–mediated elimination in vivo. The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.